<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438177</url>
  </required_header>
  <id_info>
    <org_study_id>10-02008</org_study_id>
    <nct_id>NCT01438177</nct_id>
  </id_info>
  <brief_title>Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase II trial studies how well giving bortezomib and cyclophosphamide together&#xD;
      with chloroquine works in treating patients with relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for&#xD;
      cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to&#xD;
      stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Chloroquine may help chemotherapy drugs work better by making cancer cells more&#xD;
      sensitive to the drug. Giving bortezomib and cyclophosphamide together with chloroquine may&#xD;
      kill more cancer cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution.&#xD;
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (CR + PR After 2 Cycles)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response rate is defined as the percentage of patients who have a complete response (CR) or partial response (PR). Responses were assessed every two cycles of treatment, based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006). Per International Myeloma Working Group response criteria:&#xD;
CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow PR: &gt; 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by &gt;90% or to &lt; 200 mg/24 h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events of Grade 3 or Higher</measure>
    <time_frame>Treatment period plus 30 days post-treatment</time_frame>
    <description>Adverse events reported here were at least possibly related to the protocol therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy</measure>
    <time_frame>until clinical response (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Response of This Regimen</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Duration of response is the time from response (CR or PR) until progression of disease or relapse. Responses and progression were evaluated based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Velcade+Cyclophosphamide+Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <arm_group_label>Velcade+Cyclophosphamide+Chloroquine</arm_group_label>
    <other_name>Bendamustine HCl</other_name>
    <other_name>Treanda</other_name>
    <other_name>Bortezomib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Velcade+Cyclophosphamide+Chloroquine</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Procytox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <arm_group_label>Velcade+Cyclophosphamide+Chloroquine</arm_group_label>
    <other_name>Aralen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          2. Female subject is either post-menopausal for at least 1 year before the screening&#xD;
             visit, is surgically sterilized or if they are of childbearing potential, agree to&#xD;
             practice 2 effective methods of contraception from the time of signing the informed&#xD;
             consent form through 30 days after the last dose of VELCADE, or agree to completely&#xD;
             abstain from heterosexual intercourse. Male subjects, even if surgically sterilized&#xD;
             (ie, status postvasectomy) must agree to 1 of the following: practice effective&#xD;
             barrier contraception during the entire study treatment period and through a minimum&#xD;
             of 30 days after the last dose of study drug, or completely abstain from heterosexual&#xD;
             intercourse.&#xD;
&#xD;
          3. Diagnosis of multiple myeloma based on standard criteria as follows:&#xD;
&#xD;
             Major Criteria:&#xD;
&#xD;
             I. Plasmacytomas on tissue biopsy&#xD;
&#xD;
             II. Bone marrow plasmacytosis (&gt;30% plasma cells)&#xD;
&#xD;
             III. Monoclonal immunoglobulin spike on serum electrophoresis (IgG &gt;3.5 G/dL or IgA &gt;&#xD;
             2.0 G/dL) or kappa or lambda light chain excretion&gt; 1 G/day on 24 hour urine protein&#xD;
             electrophoresis&#xD;
&#xD;
             Minor Criteria&#xD;
&#xD;
               1. Bone marrow plasmacytosis (10 to 30% plasma cells)&#xD;
&#xD;
               2. Monoclonal immunoglobulin present but of lesser magnitude than given under major&#xD;
                  criteria&#xD;
&#xD;
               3. Lytic bone lesions&#xD;
&#xD;
               4. Normal IgM &lt; 50 mg/dL, IgA &lt; 100 mg/dL, or IgG &lt; 600 mg/dL&#xD;
&#xD;
             Any of the following sets of criteria will confirm the diagnosis of Multiple Myeloma:&#xD;
&#xD;
               -  Any two of the major criteria&#xD;
&#xD;
               -  Major criterion I plus minor criterion b, c, or d&#xD;
&#xD;
               -  Major criterion III plus minor criterion a or c&#xD;
&#xD;
               -  Minor criteria a, b and c or a, b and d&#xD;
&#xD;
          4. Measurable disease, defined as a monoclonal immunoglobulin spike on serum&#xD;
             electrophoresis of ≥ 1 Gm/dL and/or urine monoclonal immunoglobulin spike of ≥ 200&#xD;
             mg/24 hours.&#xD;
&#xD;
          5. Patients must have refractory myeloma as defined by a greater than 25% increase in&#xD;
             their M-protein. They should have progressed on a combination of VELCADE and&#xD;
             cyclophosphamide.&#xD;
&#xD;
          6. Non-secretors must have measurable protein by Freelite or measurable disease such as&#xD;
             plasmacytoma to be eligible.&#xD;
&#xD;
          7. Karnofsky performance status ≥ 50&#xD;
&#xD;
          8. Patients treated with local radiotherapy with or without a brief exposure to steroids&#xD;
             are eligible. Patients who require concurrent radiotherapy should have entry to the&#xD;
             protocol deferred until the radiotherapy is completed&#xD;
&#xD;
          9. Meets the following pretreatment laboratory criteria at Baseline (Day 1 of Cycle 1,&#xD;
             before study drug administration)&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 0.5 x 10^3/uL&#xD;
&#xD;
               -  Calculated or measured creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
         10. Age 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein (M-protein) and skin changes)&#xD;
&#xD;
          2. Plasma cell leukemia&#xD;
&#xD;
          3. Receiving steroids daily for other medical conditions, e.g., asthma, systemic lupus&#xD;
             erythematosis, rheumatoid arthritis&#xD;
&#xD;
          4. Infection not controlled by antibiotics&#xD;
&#xD;
          5. HIV infection. Patients should provide consent for HIV testing according to the&#xD;
             institution's standard practice&#xD;
&#xD;
          6. Known active hepatitis B or C&#xD;
&#xD;
          7. Patient had myocardial infarction within 6 months prior to enrollment, New York&#xD;
             Hospital Association (NYHA) Class III or IV heart failure, (see appendix D),&#xD;
             uncontrolled angina, severe uncontrolled ventricular arrhythmias, or&#xD;
             electrocardiographic evidence of acute ischemia or active conduction system&#xD;
             abnormalities. Prior to study entry, any ECG abnormality at screening must be&#xD;
             documented by the investigator as not medically relevant.&#xD;
&#xD;
          8. Diagnosed or treated for another malignancy within 3 years of enrollment, with the&#xD;
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of&#xD;
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.&#xD;
&#xD;
          9. Radiation therapy within 3 weeks before randomization. Enrollment of subjects who&#xD;
             require concurrent radiotherapy (which must be localized in its field size) should be&#xD;
             deferred until the radiotherapy is completed and 3 weeks have elapsed since the last&#xD;
             date of therapy.&#xD;
&#xD;
         10. Other serious medical or psychiatric illness that could potentially interfere with the&#xD;
             completion of treatment according to this protocol&#xD;
&#xD;
         11. Female subject is pregnant or lactating. Confirmation that the subject is not pregnant&#xD;
             must be established by a negative serum B-human chorionic gonadotropin (B hCG)&#xD;
             pregnancy test result obtained during screening. Pregnancy testing is not required for&#xD;
             postmenopausal or surgically sterilized women.&#xD;
&#xD;
         12. Patient has &gt; Grade 2 peripheral neuropathy&#xD;
&#xD;
         13. Patient has known hypersensitivity to VELCADE, boron or mannitol, quinidine or&#xD;
             quinidine derivatives or to cyclophosphamide or any component of the formulation.&#xD;
&#xD;
         14. Participation in clinical trials with other investigational agents not included in&#xD;
             this trial, within 14 days of the start of this trial and throughout the duration of&#xD;
             this trial.&#xD;
&#xD;
         15. Patients with preexisting retinal or visual field changes.&#xD;
&#xD;
         16. Patient has &gt; 1.5 x upper limit of normal Total Bilirubin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Grossbard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep;20(9):1467-73. Epub 2006 Jul 20. Erratum in: Leukemia. 2006 Dec;20(12):2220. Leukemia. 2007 May;21(5):1134.</citation>
    <PMID>16855634</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <results_first_submitted>May 14, 2015</results_first_submitted>
  <results_first_submitted_qc>May 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2015</results_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloma</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>relapsed myeloma</keyword>
  <keyword>refractory myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From Oct. 2011 to March 2013, 11 patients were enrolled to the study from New York University Langone Medical Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Velcade+Cyclophosphamide+Chloroquine</title>
          <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">Patients who were off due to disease progression</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Initiation of new therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Velcade+Cyclophosphamide+Chloroquine</title>
          <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>45-53 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54-63 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>64-73 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>74-83 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (CR + PR After 2 Cycles)</title>
        <description>Response rate is defined as the percentage of patients who have a complete response (CR) or partial response (PR). Responses were assessed every two cycles of treatment, based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006). Per International Myeloma Working Group response criteria:&#xD;
CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow PR: &gt; 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by &gt;90% or to &lt; 200 mg/24 h</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade+Cyclophosphamide+Chloroquine</title>
            <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (CR + PR After 2 Cycles)</title>
          <description>Response rate is defined as the percentage of patients who have a complete response (CR) or partial response (PR). Responses were assessed every two cycles of treatment, based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006). Per International Myeloma Working Group response criteria:&#xD;
CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow PR: &gt; 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by &gt;90% or to &lt; 200 mg/24 h</description>
          <population>Evaluable patients.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events of Grade 3 or Higher</title>
        <description>Adverse events reported here were at least possibly related to the protocol therapy.</description>
        <time_frame>Treatment period plus 30 days post-treatment</time_frame>
        <population>Any patients who started the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade+Cyclophosphamide+Chloroquine</title>
            <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Grade 3 or Higher</title>
          <description>Adverse events reported here were at least possibly related to the protocol therapy.</description>
          <population>Any patients who started the treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal cavity/paranasal reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC/AGC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: pleural</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy</title>
        <time_frame>until clinical response (up to 2 years)</time_frame>
        <population>Study was terminated prior to collection of this data point.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade+Cyclophosphamide+Chloroquine</title>
            <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy</title>
          <population>Study was terminated prior to collection of this data point.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Response of This Regimen</title>
        <description>Duration of response is the time from response (CR or PR) until progression of disease or relapse. Responses and progression were evaluated based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006).</description>
        <time_frame>up to 2 years</time_frame>
        <population>patients who have responded</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade+Cyclophosphamide+Chloroquine</title>
            <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Response of This Regimen</title>
          <description>Duration of response is the time from response (CR or PR) until progression of disease or relapse. Responses and progression were evaluated based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006).</description>
          <population>patients who have responded</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment and within 30 days post-treatment</time_frame>
      <desc>All adverse events were reported regardless of attribution to protocol therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Velcade+Cyclophosphamide+Chloroquine</title>
          <description>VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.&#xD;
Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.&#xD;
Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.&#xD;
Each cycle is 42 days in length.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pain: pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC):</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dental: teeth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L):</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infection - Other: ocular Hepes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infection - Other: shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils: Eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Skin (cellulites)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Opportunistic infection associated with &gt;=Grade 2 Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other: high BUN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Joint</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Muscle</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mood alteration: Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mood alteration: Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain: Breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Testicle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain: Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel injury-vein: Other NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amitabha Mazumder, MD</name_or_title>
      <organization>Perlmutter Cancer Center</organization>
      <phone>212-731-5757</phone>
      <email>amitabha.mazumder@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

